CTEN/TNS4 is an oncogene in colorectal cancer (CRC), which can induce cell motility although its mechanistic basis of activity and the clinical implications of Cten expression are unknown. As Cten is in complex with integrins at focal adhesions, we hypothesised that it may interact with integrin-linked kinase (ILK). Through forced expression and knockdown of Cten in HCT116 and SW620 (respectively, showing low and high Cten expression), we showed that Cten could regulate ILK. However, inhibition of ILK after forced expression of Cten abrogated the motility-inducing effects of Cten, thereby demonstrating that the Cten-ILK interaction was functionally relevant. Combined knockdown of Cten and ILK had no additive effects on cell motility compared with knockdown of each individually. In order to investigate the clinical implications of Cten expression, a series of 462 CRCs were evaluated by immunohistochemistry. High expression of Cten was associated with advanced Dukes' stage (Po0.001), poor prognosis (Po0.001) and distant metastasis (P ¼ 0.008). The role of Cten in metastasis was tested by (a) intrasplenic injection of CRC cells stably transfected with a Cten expression vector into nude mice and (b) testing a series of primary human CRCs and their metastases by immunohistochemistry. Compared with controls, mice injected with cells expressing Cten developed larger tumours in the spleen (Po0.05) and liver (Po0.05). In the human cases, compared with primary tumours, the metastatic deposits had a significantly higher frequency of nuclear localisation of Cten (P ¼ 0.002). We conclude that Cten expression is of prognostic significance in CRC, and we delineate a Cten-ILK pathway controlling cell motility and possibly promoting metastasis.
CTEN/TNS4 is an oncogene in colorectal cancer (CRC), which can induce cell motility although its mechanistic basis of activity and the clinical implications of Cten expression are unknown. As Cten is in complex with integrins at focal adhesions, we hypothesised that it may interact with integrin-linked kinase (ILK). Through forced expression and knockdown of Cten in HCT116 and SW620 (respectively, showing low and high Cten expression), we showed that Cten could regulate ILK. However, inhibition of ILK after forced expression of Cten abrogated the motility-inducing effects of Cten, thereby demonstrating that the Cten-ILK interaction was functionally relevant. Combined knockdown of Cten and ILK had no additive effects on cell motility compared with knockdown of each individually. In order to investigate the clinical implications of Cten expression, a series of 462 CRCs were evaluated by immunohistochemistry. High expression of Cten was associated with advanced Dukes' stage (Po0.001), poor prognosis (Po0.001) and distant metastasis (P ¼ 0.008). The role of Cten in metastasis was tested by (a) intrasplenic injection of CRC cells stably transfected with a Cten expression vector into nude mice and (b) testing a series of primary human CRCs and their metastases by immunohistochemistry. Compared with controls, mice injected with cells expressing Cten develIntroduction C-terminal tensin-like (Cten, TNS4) is a member of the Tensin gene family. This gene family comprises four members (TNS1, TNS2, TNS3 and TNS4/Cten) and their products are localised to the cytoplasmic tails of integrins at focal adhesions. Tensins have an important role in various biological processes such as cell adhesion, migration, proliferation, differentiation, apoptosis and invasion (Lo et al., 1994; Chen et al., 2000; Lo, 2004) . Human TNS1, TNS2 and TNS3 are highly homologous at their N-and C-termini, but TNS4/ COOH-terminus tensin-like molecule (Cten) is a smaller protein, which shows C-terminus homology but does not contain the N-terminus actin-binding domain that is present in the other tensin proteins (Lo and Lo, 2002) . Tensin family proteins interact with several structural and signalling molecules such as vinculin, paxillin, Src, focal adhesion kinase, phosphatidylinositol-3-kinase and Crk-associated substrate p130 CAS , actin as well as integrins. As Cten is a recently described gene, data about its downstream targets are sparse, although recent studies suggest that Cten signalling occurs through the Stat3 pathway (Barbieri et al., 2010) .
Although Cten acts as a tumour suppressor in prostate cancer (Lo and Lo, 2002) , in many cancers including breast cancer and colorectal cancer (CRC), it acts as an oncogene (Katz et al., 2007; Albasri et al., 2009; Liao et al., 2009) . We have recently shown that high levels of Cten expression are associated with a poor prognosis in breast cancer (Albasri et al., 2011) , and similar results have been reported in thymomas, gastric cancers and lung cancers (Sasaki et al., 2003a, b; Sakashita et al., 2008) . The impact of Cten expression on clinical outcome may be related to its biological activity, which, in CRC cell lines at least, results in enhanced colony formation, resistance to staurosporineinduced apoptotic stress and increased cell motility (Albasri et al., 2009; Liao et al., 2009) . However, the prognostic value of Cten expression in CRCs has hitherto not been reported.
In this study, we sought to further investigate the role of Cten in CRC. Given that both Cten and integrinlinked kinase (ILK) seem to regulate cell motility and downregulate E-cadherin (Somasiri et al., 2001; Oloumi et al., 2004; McPhee et al., 2008) , we hypothesised that Cten may signal through ILK. In addition, we evaluated the prognostic significance of Cten in a series of CRC and we used an in vivo model to test whether Cten could influence tumour metastasis. Finally, we examined the association between Cten expression and tumour metastasis in a series of paired primary tumours and corresponding metastatic deposits.
Results and discussion
Cten and ILK signalling We tested the hypothesis that Cten may function through ILK signalling using a dual approach of forced ectopic Cten expression and Cten knockdown (using small interfering RNA) in cell lines expressing low and high levels of Cten protein, respectively. This approach helps to obviate any non-specific or off-target effects, which are known confounders with each of these methods individually. Western blots showed that forced expression of green fluorescent protein (GFP)-tagged Cten in the CRC cell line HT116 (denoted HCT116 ) or scrambled control small interfering RNAs (HCT116 ssc/GFPÀCten ). The western blots show that the protein levels had been appropriately manipulated. The presence of Cten caused enhanced motility compared with the empty vector controls (Po0.001), but knockdown of ILK in the presence of Cten resulted in significant reduction in transwell cell migration (P ¼ 0.006). (d) Both ILK and Cten were knocked down in combination with SW620 (SW620 CtenÀ/ILKÀ ), and compared with each knocked down individually (SW620 CtenÀ/ssc and SW620 ILKÀ/ssc ) or scrambled control (SW620 ssc/ssc ). The western blots show that the protein levels had been appropriately manipulated. There was no additive effect of combined knockdown, suggesting that ILK lies downstream of Cten. EVC, empty vector control; SSC, scrambled sequence controls. Figure 1b) . Our data showed that induced upregulation and downregulation of Cten were mirrored by similar changes in ILK protein expression. We next tested whether there was any functional relevance to these changes by creating a condition whereby Cten was forcibly expressed but ILK was depleted. The cell line HCT116 was co-transfected with ILK-specific small interfering RNA and the GFP-Cten expression vector ( ). Knockdown of Cten and ILK produced similar levels of inhibition of cell migration compared with controls, but there was no additive effect seen when both proteins were knocked down simultaneously (Figure 1d) .
Taken together, these data show that ILK is regulated by Cten and that it is involved in mediating Cteninduced cell motility. The functional relevance of this relationship was confirmed by demonstrating that knockdown of ILK inhibited the motility-inducing effects of ectopic Cten expression. The lack of additive effect when both Cten and ILK were knocked down together suggests that a large proportion of the motility induction by Cten is mediated through ILK.
Cten expression and prognosis
The clinical relevance of Cten expression was tested by evaluating immunohistochemical expression in a tissue microarray of 462 primary tumours from patients who underwent elective surgery between 1 January 1993 and 31 December 2000 at the Nottingham University Hospitals, Queen's Medical Centre, Nottingham, UK. This resource has been well characterised and has been previously described (Ullenhag et al., 2007; Ahmed et al., 2009) . Patient characteristics and clinico-pathological details are summarised in Supplementary Table 1. After exclusion of non-informative tissue microarray cores from the study, 317 tumour tissue cores were available and these were assessed using the H-score (see Supplementary data for full description). The staining pattern for Cten in tumour cells was predominantly heterogeneous and cytoplasmic. In the whole series, 287/ 317 (90%) of the tumours showed some expression for Cten. Patchy focal nuclear staining was seen in 20/317 (6%) of cases, but no tumour cell membrane or stromal expression of Cten was noticed in any of the examined cases. The X-tile bio-informatics software (http:// www.tissuearray.org) (Camp et al., 2004) defined optimal cut-off points of the Cten H-score at 150, allowing cases to be dichotomised as 'low' Cten (H score o150) or 'high Cten' (H score 4150, Figure 2a) . Table 1 summarises the associations between Cten cytoplasmic expression and clinico-pathological variables. High Cten expression was significantly associated with advanced Dukes stage (P ¼ 0.001), lymph node metastasis (Po0.001), extra-mural vascular invasion (P ¼ 0.001) and distant metastases (P ¼ 0.008). However, Cten expression was not significantly associated with patient age, gender, tumour histological type, tumour grade and tumour site. Univariate survival analysis showed that patients with high Cten tumour expression had significantly shorter disease-free survival (Po0.001, Figure 2b ) and poorer overall survival than those with low Cten expression (Po0.001). However, multivariate Cox proportional hazard analysis including TNM (tumour, node, metastasis) stage, vascular invasion and Cten expression showed that Cten expression was of borderline significance as an independent predictor of disease-free survival in CRC (P ¼ 0.071, Table 1 ). This is the largest study to date to evaluate the prognostic significance of Cten expression in CRC. Although multivariate analysis showed that Cten expression was not quite a statistically significant independent predictor of disease-free survival in CRC, our data showing the association of high Cten expression with poor prognostic clinico-pathologic variables and outcome are consistent with studies in several other types of tumour, in which Cten acts as an oncogene and in which high Cten expression is associated with poor outcome. High Cten expression confers a number of properties to a tumour cell, such as induction of epithelial to mesenchymal transition and enhanced colony-forming abilities, which may be the biological basis of the observed association with advanced disease and poor prognosis (Albasri et al., 2009; Liao et al., 2009) .
Nuclear expression of Cten in CRC has been described in other studies and was confirmed in our study. However, the number of cases showing nuclear expression was small (6% of the total study group), and although this study found a shift to the nucleus in metastatic deposits (see below), nuclear expression in the primary tumour per se was not correlated with clinicopathological parameters or outcome in CRC.
Cten and induction of tumour metastasis in vivo Enhanced cell motility is an important part of the process of tumour metastasis. Our in vitro data show unequivocally that Cten has a role in stimulating cell motility in CRC, and our analysis of human tumours demonstrated an association between high Cten expression in the primary tumour and metastasis. This prompted us to scale up our investigations to test whether Cten could influence the metastatic process in vivo. HCT116 cells were stably transfected with either GFP-Cten (HCT116 GFP-Cten ) or GFP empty vector (HCT116 evc ), and injected into the spleens of nude mice (n ¼ 10 in each group). Compared with the HCT116 evc controls, mice injected with cells expressing HCT116
GFPÀCten developed a significantly greater total tumour burden in the spleen (average intra-splenic tumour volume for HCT116
GFPÀCten and HCT116 evc were 89 and 4 mm 3 , respectively, P ¼ 0.03, Mann-Whitney U test, Figure 3a) . The number of discrete tumour deposits in the liver was similar in both groups, but the size of the deposits was greater in HCT116 GFPÀCten , leading to a greater tumour burden (average intrahepatic tumour volume for HCT116 GFPÀCten and HCT116 evc were 26 and 2 mm 3 , respectively, P ¼ 0.05; Mann-Whitney U test, Figure 3b ). In addition, mice injected with cells expressing HCT116
GFPÀCten had a shorter overall survival than controls ( Supplementary  Figure 2) .
Thus, mice injected with GFP-Cten-expressing cells developed a greater tumour burden both locally within the spleen and within the liver metastases and had shorter survival. These data would suggest that Cten can indeed enhance tumour metastasis, and would support our own data and other published data showing the association between high Cten expression and advanced disease stage in colorectal, breast, lung, thymic and gastric tumours (Sasaki et al., 2003a, b; Sakashita et al., 2008; Albasri et al., 2011) .
Cten expression in metastatic deposits in CRC
To investigate further the role of Cten in tumour metastasis, a series of 40 cases of paired primary CRC and corresponding hepatic metastasis deposits was tested for Cten expression by immunohistochemistry. Both primary and metastatic tumours showed similar levels of cytoplasmic staining. However, metastatic deposits were significantly associated with a shift of Cten expression to the nucleus (P ¼ 0.002, Figure 3c , Supplementary Table 2) when compared with their corresponding primaries. The significance of nuclear localisation of Cten to the metastatic process is uncertain; within the nucleus, it can be found in complex with b-catenin and it may thus contribute to establishment of metastatic deposits through modulation of Wnt signalling (Liao et al., 2009) .
In summary, the evidence that Cten has a role in regulating cell motility seems compelling. We have shown that Cten manipulation in a further two CRC cell lines (DLD1 and Colo205) also results in altered cell motility (see Supplementary Figure 3 ). Taken together with our previously published data, Cten has been shown to influence motility in five different CRC cell lines. The data have been consistent whether the test has been to knock down Cten (resulting in reduced motility) or forcibly expressed Cten (resulting in increased motility). The data herein show that the motility may be mediated through ILK and also that it may be clinically relevant to development of tumour metastasis. If this is confirmed, then Cten may become a therapeutic target in cancer. Further studies are currently necessary to dissect out the exact mechanisms of Cten activity and regulation. High Cten expression was associated with advanced disease and poor prognostic features. The P-values shown in bold are provided by the stats package. 
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